IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 67.00
Bid: 66.00
Ask: 68.00
Change: 8.25 (14.04%)
Spread: 2.00 (3.03%)
Open: 59.50
High: 67.75
Low: 62.00
Prev. Close: 58.75
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta collaboration programme gets £3.8m grant

Wed, 10th Aug 2016 09:28

(ShareCast News) - A collaboration programme between AIM-listed Avacta and Leeds University has been awarded a £3.8m grant by the Medical Research Council.The biotherapeutics and research reagents developer said the grant was to develop novel, rapid diagnostic tools incorporating Affimer reagents, to differentiate between viral and bacterial infections, and differentiate bacterial strains.The programme will develop next generation biosensors to differentiate between bacterial and viral infections and determine which bacterial strain has caused the infection so the correct antibiotic can be administered quickly. This will reduce the number of wrongly-prescribed treatments and increase efficacy for patients, which will contribute to a reduction in anti-microbial resistance (AMR).Affimer technology is an engineered alternative to antibodies that can capture a target, such as a bacterial or viral protein, with a high degree of specificity.Chief executive Alastair Smith said: "I am delighted that the potential of Affimer reagents to improve rapid diagnostics has been recognised by the Medical Research Council through this substantial funding. The combination with the innovative microfluidic devices developed at Leeds University is very promising and could lead to a new class of rapid test device."There is a growing, global need for diagnostic tests that differentiate bacterial strains. Anti-microbial resistance is a huge issue for healthcare providers and one that is only going to get worse if the prescription of antibiotics is not targeted by accurate and rapid diagnostics. This programme fits perfectly with our near term commercial strategy to focus on developing Affimer reagents for rapid diagnostics."At 0940 BST, Avacta shares were up 12% to 110p.
More News
11 Aug 2014 10:22

Monday broker round-up UPDATE

Avacta Group: Numis lowers target price from 2p to 1.6p retaining its buy recommendation. Braemer Shipping Services: Westhouse Securities reinstates with a target price of 545p and a buy recommendation. British Land: Liberum Capital upgrades to buy with a target price of 763p. Catlin Group: Deuts

Read more
4 Aug 2014 08:54

Avacta Group Launches New OPTIM Variants As It seeks new Customers

Read more
1 Aug 2014 10:58

UK MIDDAY BRIEFING: Smith & Nephew Confident In Outlook

Read more
1 Aug 2014 10:36

UK WINNERS & LOSERS: Smith & Nephew, Rexam Lead Few FTSE 100 Risers

Read more
1 Aug 2014 10:33

Friday broker round-up UPDATE

AstraZeneca: Deutsche Bank ups target price from 3950p to 4000p staying with its hold recommendation. Avacta: Numis places both its target price and its buy recommendation under review. Barclays: Berenberg upgrades from sell to hold with a target price of 220p. Bodycote: UBS shifts target price f

Read more
1 Aug 2014 08:22

Avacta Group Falls On Sensipod Delays, North America Problems

Read more
23 Jul 2014 14:17

Sector movers: Weak results, outlook from Glaxo sink pharma stocks

A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a

Read more
15 Jul 2014 10:08

Avacta Appoints Cosmo Bio As Japanese Distributor For Affimers

Read more
4 Jun 2014 09:28

Wednesday broker round-up UPDATE

Advanced Computer Software: Panmure Gordon ups target price from 139p to 155p and stays with its buy recommendation. Avacta: Numis shifts target price from 1.9p to 2p and retains a buy recommendation. Balfour Beatty: Westhouse Securities reduces target price from 302p to 220p keeping its neutral r

Read more
4 Jun 2014 09:07

UK BROKER RATINGS: Morgan Stanley Cuts SABMiller To Equal-Weight

LONDON (Alliance News) - The following UK shares received analyst recommendations Wednesday morning:
----------
FTSE 100
----------
NOMURA RAISES REED ELSEVIER PRICE TARGET TO 1050 (975) PENCE - 'BUY'
----------
CITIGROUP CUTS TULLOW OIL PRICE TA

Read more
2 Jun 2014 09:04

Avacta Gets Funding Award To Support Affirmer Development

LONDON (Alliance News) - Avacta Group PLC Monday said it had secured a funding award from the UK's innovation agency to support it in developing affirmer technology as a potential way of helping develop new cancer treatments. The company is developing affimers, which are engineered alternat

Read more
9 May 2014 10:34

Avacta In Collaboration Deal With UbiQ To Develop Ubiquitin Reagents

LONDON (Alliance News) - Avacta Group PLC Friday said it has signed a collaboration deal with ubiquitylated peptides supplier UbiQ Bio under which the companies will work together to develop reagents that specifically bind to ubiquitin chains. Avacta makes diagnostic tools, consumables and

Read more
9 May 2014 08:30

Avacta collaborates with UbiQ Bio

AIM-listed pharmaceuticals company Avacta Group announced it has signed a collaboration deal with proteins provider UbiQ Bio to build up its chain of ubiquitin Affimers. The group will be providing Avacta with small proteins found in humans and animals to further the firm's development of Affimers

Read more
7 May 2014 10:18

REPEAT: Avacta Raises GBP10.1M In Placing With Additional Option

LONDON (Alliance News) - Avacta Group PLC Wednesday said it has raised GBP10.1 million before expenses through a share placing on 918.2 million shares, which it will use to accelerate the development and commercialisation of Affimers. The shares were placed with both new and existing instit

Read more
7 May 2014 10:16

Avacta Raises GBP10.1M In Share Placing With Additional Option

LONDON (Alliance News) - Avacta Group PLC Wednesday said it has raised GBP10.1 million before expenses through a share placing on 918.2 million shares, which it will use to accelerate the development and commercialisation of Affimers. The shares were placed with both new and existing instit

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.